MedTrace Logo

Mood and Cognitive Effects of Psilocybin in Healthy Participants

NCT05252598 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2023-03-20

No results posted yet for this study

Summary

This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects.

Conditions

  • Mood Disturbance
  • Mood Change
  • Sleep Disturbance
  • Drug Effect
  • Psychedelic Experiences
  • Health, Subjective
  • Psilocin Toxicity
  • Psilocybin Toxicity
  • Psilocybin Causing Adverse Effects in Therapeutic Use
  • Anxiety

Interventions

DRUG

Psilocybin

1mg encapsulated psilocybin

DRUG

Inonotus Obliquus Whole Extract

1mg encapsulated chaga mushroom

Sponsors & Collaborators

  • University of Calgary

    collaborator OTHER

  • Optimi Health Corporation

    lead INDUSTRY

Principal Investigators

  • Valerie Taylor, MD/PhD · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2023-08-31
Completion
2023-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05252598 on ClinicalTrials.gov